Method
Level · gp.fundamentals.capex_revenue_ratio
Raw value 0.00% · OPTIONAL
· Pharmaceutical Preparations
RESEARCH SNAPSHOTArcturus Therapeutics Holdings Inc.'s latest supported as-filed period reports revenue of $3.0M, 89.5% below the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.capex_revenue_ratio
Raw value 0.00% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -672.86% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value -89.54% · CORE
Level · gp.fundamentals.operating_margin
Raw value -863.30% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 591.92% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 142.99% · OPTIONAL
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Operating income changed -119.9% from the comparable as-filed period. The change ranks at the 54th percentile of 52 prior comparable changes.
Revenue changed -89.5% from the comparable as-filed period. The change ranks at the 67th percentile of 52 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
ARCT · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001193805-26-001130SEC ↗10-QAug 6, 2026Period Jun 30, 20260001193125-26-338090SEC ↗8-KAug 6, 2026Period Aug 6, 20260001193805-26-001039SEC ↗8-KJul 2, 2026Period Jun 26, 20260001193805-26-000910SEC ↗4Jun 15, 2026Period Jun 5, 20260001193805-26-000829SEC ↗4Jun 15, 2026Period Jun 5, 20260001193805-26-000828SEC ↗4Jun 15, 2026Period Jun 5, 20260001193805-26-000827SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Jun 5, 2026Filed Jun 15, 2026 | HOLMES EDWARD WDirector | Grant Or AwardDirect | 15,000 | $0 | $0 | Form 4 ↗ |
| Jun 5, 2026Filed Jun 15, 2026 | FARRELL PETER CDirector | Grant Or AwardDirect | 15,000 | $0 | $0 | Form 4 ↗ |
| Jun 5, 2026Filed Jun 15, 2026 | BARLOW JAMES FDirector | Grant Or AwardDirect | 15,000 | $0 | $0 | Form 4 ↗ |
| Jun 5, 2026Filed Jun 15, 2026 | Markels JohnDirector | Grant Or AwardDirect | 15,000 | $0 | $0 | Form 4 ↗ |
| Jun 5, 2026Filed Jun 15, 2026 |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Operating margin changed -82225 basis points from the comparable as-filed period. The change ranks at the 60th percentile of 52 prior comparable changes.
Net income changed -159.1% from the comparable as-filed period. The change ranks at the 66th percentile of 67 prior comparable changes.
Research & development changed -40.8% from the comparable as-filed period. The change ranks at the 63th percentile of 52 prior comparable changes.
Stock-based compensation changed -31.8% from the comparable as-filed period. The change ranks at the 46th percentile of 52 prior comparable changes.
SBC / revenue changed +12108 basis points from the comparable as-filed period. The change ranks at the 60th percentile of 52 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001193805-26-000826| Grant Or AwardDirect |
| 15,000 |
| $0 |
| $0 |
| Form 4 ↗ |
| Jun 5, 2026Filed Jun 15, 2026 | Marquet MagdaDirector | Grant Or AwardDirect | 15,000 | $0 | $0 | Form 4 ↗ |
| Jun 5, 2026Filed Jun 15, 2026 | Marantz Jing L.Director | Grant Or AwardDirect | 15,000 | $0 | $0 | Form 4 ↗ |
| May 1, 2026Filed May 7, 2026 | MULROY DENNISChief Financial Officer | Grant Or AwardDirect | 100,000 | $0 | $0 | Form 4 ↗ |
| Dec 17, 2025Filed Dec 19, 2025 | Roberts JosephController | Grant Or AwardDirect | 10,000 | $0 | $0 | Form 4 ↗ |
| Dec 17, 2025Filed Dec 19, 2025 | Chivukula PadChief Scientific Officer & COO | Grant Or AwardDirect | 54,000 | $0 | $0 | Form 4 ↗ |
| Dec 17, 2025Filed Dec 19, 2025 | Payne Joseph EPresident and CEO | Grant Or AwardDirect | 175,000 | $0 | $0 | Form 4 ↗ |
| Dec 17, 2025Filed Dec 19, 2025 | Kurata LanceChief Legal Officer | Grant Or AwardDirect | 54,000 | $0 | $0 | Form 4 ↗ |